Free Trial
ETR:BAYN

Bayer Aktiengesellschaft (BAYN) Stock Price, News & Analysis

Bayer Aktiengesellschaft logo
€22.99 +0.51 (+2.27%)
As of 04/25/2025

About Bayer Aktiengesellschaft Stock (ETR:BAYN)

Key Stats

Today's Range
€22.42
€23.14
50-Day Range
€19.47
€24.86
52-Week Range
€24.96
€44.28
Volume
3.78 million shs
Average Volume
N/A
Market Capitalization
$23.21 billion
P/E Ratio
N/A
Dividend Yield
0.48%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health. The Crop Science segment offers seeds, improved plant traits, innovative chemical and biological crop protection products, digital solutions, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration with Acuitas Therapeutics, Inc. to strengthen gene editing programs; Peking University in the area of basic pharmaceutical research; the Swiss Tropical and Public Health Institute in the development of the compound emodepside for the treatment of infection with soil-transmitted helminths; bit.bio Ltd. for the discovery and manufacture of regulatory T cells for use in creating therapeutics; Hologic, Inc. in the field of contrastenhanced-mammography solutions to improve diagnostic imaging for the detection of breast cancer; and Twist Bioscience Corporation centering around the research and development of antibody-based pharmaceuticals, as well as with CrossBay Medical Inc. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company has collaboration with Thermo Fisher Scientific. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

Receive BAYN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bayer Aktiengesellschaft and its competitors with MarketBeat's FREE daily newsletter.

BAYN Stock News Headlines

Bayer AG (BAYN.HA)
Aktionäre gehen mit Bayer auf Hauptversammlung hart ins Gericht
Real Americans Don’t Wait on Wall Street’s Next Move
What's happening in the markets right now should concern every freedom-loving American who's worked hard and saved smart. Your 401(k) doesn't deserve to be dragged through the mud by tariffs, trade wars, reckless spending, and political standoffs. And you don't have to stand by while Wall Street plays roulette with your future.
Bayer-Aktie: Es kracht gewaltig!
Bayer AG Aktie: Erfolgreiche Tage liegen an!
See More Headlines

BAYN Stock Analysis - Frequently Asked Questions

Bayer Aktiengesellschaft's stock was trading at €19.31 on January 1st, 2025. Since then, BAYN stock has increased by 19.0% and is now trading at €22.99.
View the best growth stocks for 2025 here
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bayer Aktiengesellschaft investors own include Hawkins (HWKN), NVIDIA (NVDA), Meta Platforms (META), Alibaba Group (BABA), Basf (BAS), Volkswagen (VOW3) and Bayerische Motoren Werke Aktiengesellschaft (BMW).

Industry, Sector and Symbol

Stock Exchange
ETR
Sector
Medical
Industry
Drug Manufacturers - General
Sub-Industry
N/A
Current Symbol
ETR:BAYN
CIK
N/A
Fax
N/A
Employees
96,931
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
4.26
P/E Growth
36.39
Net Income
$-904,331,613.41
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$48.03 billion
Cash Flow
€4.02 per share
Price / Cash Flow
5.73
Book Value
€31.24 per share
Price / Book
0.74

Miscellaneous

Outstanding Shares
1,009,583,481
Free Float
N/A
Market Cap
$23.21 billion
Optionable
Not Optionable
Beta
0.97
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (ETR:BAYN) was last updated on 4/27/2025 by MarketBeat.com Staff
From Our Partners